Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28007152 | 0.94 | SLC22A6 (0.51) | SLC22A6ATMGPR84MEN1CYP3A4 | |
| SCHEMBL31744738 | 0.91 | SMN1; SMN2 (0.54) | SLC22A6GPR84MEN1MAPTAHR | |
| SCHEMBL31744932 | 0.91 | SLC22A6 (0.50) | SLC22A6ATMGPR84MEN1KMT2A | |
| SCHEMBL31744658 | 0.91 | SLC22A6 (0.50) | SLC22A6ATMGPR84MEN1CYP3A4 | |
| SCHEMBL31744565 | 0.91 | SLC22A6 (0.46) | SLC22A6ATMGPR84MEN1CYP3A4 | |
| SCHEMBL27396972 | 0.91 | RHEB (0.51) | SLC22A6ATMMAPTTP53NPSR1 | |
| SCHEMBL3538344 | 0.89 | SLC22A6 (0.58) | SLC22A6ATMGPR84MEN1CYP3A4 | |
| SCHEMBL31744736 | 0.87 | STING1 (0.49) | SLC22A6 | |
| SCHEMBL4920498 | 0.87 | STING1 (0.49) | SLC22A6GPR84MEN1MAPTKMT2A | |
| SCHEMBL4923715 | 0.85 | SLC22A6 (0.60) | SLC22A6GPR84MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | SLC22A6 832/4885ATM 1153/4885GPR84 1593/4885 |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | SLC22A6 819/4885ATM 1146/4885GPR84 1600/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | SLC22A6 819/4885ATM 1146/4885GPR84 1600/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | SLC22A6 819/4885ATM 1146/4885GPR84 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.